Esther Holgado

20.7k total citations
42 papers, 870 citations indexed

About

Esther Holgado is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Esther Holgado has authored 42 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Esther Holgado's work include Cancer Immunotherapy and Biomarkers (22 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (10 papers). Esther Holgado is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Treatment and Pharmacology (10 papers). Esther Holgado collaborates with scholars based in Spain, United States and Italy. Esther Holgado's co-authors include Javier Cortés, José Manuel Pérez-García, Peter Schmid, Seock‐Ah Im, Sherene Loi, Gursel Aktan, Julie R. Brahmer, Leora Horn, Everett E. Vokes and David R. Spigel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Esther Holgado

41 papers receiving 855 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esther Holgado Spain	15	757	367	207	169	129	42	870
Tina C. Young United States	10	917 1.2×	565 1.5×	269 1.3×	127 0.8×	139 1.1×	18	1.1k
Wilbur Pan United States	8	614 0.8×	231 0.6×	178 0.9×	246 1.5×	115 0.9×	19	783
Marco Torregroza Otero Spain	6	651 0.9×	258 0.7×	198 1.0×	233 1.4×	104 0.8×	7	800
Gabriele Minuti Italy	12	665 0.9×	515 1.4×	119 0.6×	164 1.0×	229 1.8×	35	911
Luis Paz Ares Spain	7	462 0.6×	262 0.7×	154 0.7×	99 0.6×	188 1.5×	10	665
Elvire Pons‐Tostivint France	13	468 0.6×	351 1.0×	86 0.4×	134 0.8×	238 1.8×	47	764
Johnathan Man Australia	6	1.0k 1.3×	847 2.3×	152 0.7×	179 1.1×	134 1.0×	11	1.1k
Elena Poddubskaya Russia	16	478 0.6×	269 0.7×	129 0.6×	236 1.4×	312 2.4×	57	846
Delphine Topart France	12	425 0.6×	234 0.6×	85 0.4×	231 1.4×	122 0.9×	29	606
Jinpeng Shi China	13	566 0.7×	446 1.2×	141 0.7×	169 1.0×	261 2.0×	27	840

Countries citing papers authored by Esther Holgado

Since Specialization

Citations

This map shows the geographic impact of Esther Holgado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Holgado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Holgado more than expected).

Fields of papers citing papers by Esther Holgado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther Holgado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Holgado. The network helps show where Esther Holgado may publish in the future.

Co-authorship network of co-authors of Esther Holgado

This figure shows the co-authorship network connecting the top 25 collaborators of Esther Holgado. A scholar is included among the top collaborators of Esther Holgado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther Holgado. Esther Holgado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dent, Rebecca, Javier Cortés, Eva Muñoz‐Couselo, et al.. (2025). Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Research. 27(1). 35–35. 3 indexed citations

Holgado, Esther, et al.. (2023). Overcoming barriers to opioid-induced constipation management in cancer patients. Seminars in Oncology. 50(6). 149–154. 1 indexed citations

Sampayo-Cordero, Miguel, José Manuel Pérez-García, David Páez, et al.. (2020). Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design. Contemporary Clinical Trials Communications. 20. 100678–100678. 3 indexed citations

Yusof, Mastura Md, David W. Cescon, Hope S. Rugo, et al.. (2020). 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia. Annals of Oncology. 31. S1257–S1257. 3 indexed citations

Cortés, Javier, David W. Cescon, Hope S. Rugo, et al.. (2020). KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1000–1000. 137 indexed citations

Holgado, Esther, José Manuel Pérez-García, María Gión, & Javier Cortés. (2018). Is there a role for immunotherapy in HER2-positive breast cancer?. npj Breast Cancer. 4(1). 21–21. 20 indexed citations

Quiroga, Vanesa, Esther Holgado, José Luis Alonso-Romero, et al.. (2018). Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast. Annals of Oncology. 29. x32–x32. 1 indexed citations

Ignatiadis, Michail, Gert Van den Eynden, Marco Fornili, et al.. (2018). Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. JNCI Journal of the National Cancer Institute. 111(1). 69–77. 58 indexed citations

Cortés, Javier, José Manuel Pérez-García, Christelle Lévy, et al.. (2018). Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. Annals of Oncology. 29(4). 881–887. 5 indexed citations

10.

Schmid, Peter, Yeon Hee Park, Eva Muñoz‐Couselo, et al.. (2017). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. Journal of Clinical Oncology. 35(15_suppl). 556–556. 68 indexed citations

11.

Cortés, Javier, Seock‐Ah Im, Esther Holgado, et al.. (2017). The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treatment Reviews. 61. 53–60. 35 indexed citations

12.

Font, E. Felip, Scott Gettinger, Scott Antonia, et al.. (2017). Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v462–v462. 22 indexed citations

13.

Nucíforo, Paolo, Aleix Prat, Antonio Llombart‐Cussac, et al.. (2017). Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial. Annals of Oncology. 28. v46–v46. 7 indexed citations

14.

Calvo, Emiliano, Víctor Moreno, Michael Flynn, et al.. (2017). Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Annals of Oncology. 28(10). 2559–2566. 65 indexed citations

15.

Gagliato, Débora De Melo, Javier Cortés, Giuseppe Curigliano, et al.. (2017). Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1868(2). 527–537. 57 indexed citations

16.

Horn, Leora, Julie R. Brahmer, Martin Reck, et al.. (2015). 417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs). Annals of Oncology. 26. ix125–ix125. 7 indexed citations

17.

Calvo, Emiliano, Valentina Boni, Rebecca S. Heist, et al.. (2014). Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc. Annals of Oncology. 25. iv429–iv429. 6 indexed citations

18.

Espinosa, Javier, Aranzazu González del Alba, F. Rivera Herrero, & Esther Holgado. (2012). SEOM guidelines for the treatment of bone metastases from solid tumours. Clinical & Translational Oncology. 14(7). 505–511. 13 indexed citations

19.

Holgado, Esther, et al.. (2011). An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment. SHILAP Revista de lepidopterología. 4(3). 583–586. 9 indexed citations

20.

Grávalos, Cristina, et al.. (2007). Role of Tyrosine Kinase Inhibitors in the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer. 6(10). 691–699. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact